Anti-Disialoganglioside-2 Monoclonal Antibodies as an Emerging Therapeutic Approach in Treatment of High-Risk Neuroblastoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pudela C, Balyasny S, Applebaum MA. Nervous system: embryonal tumors: neuroblastoma. Atlas of genetics and cytogenetics in oncology and haematology. 2020;24(7):284–90. https://doi.org/10.4267/2042/70771.
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11. https://doi.org/10.1056/NEJMra0804577.
Johnsen JI, Dyberg C, Wickström M. Neuroblastoma—a neural crest derived embryonal malignancy. Front Mol Neurosci. 2019;12:9. https://doi.org/10.3389/fnmol.2019.00009.
Horta ZP, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 2016;8(9):1097–117. https://doi.org/10.2217/imt-2016-0021.
Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. JCO. 2009;27(2):289–97. https://doi.org/10.1200/JCO.2008.16.6785.
Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018;5(9):114. https://doi.org/10.3390/children5090114.
London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, et al. Phase II Randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a children’s oncology group study. JCO. 2010;28(24):3808–15. https://doi.org/10.1200/JCO.2009.27.5016.
Park JR, Stewart CF, London WB, Santana VM, Shaw PJ, Cohn SL, et al. A topotecan-containing induction regimen for treatment of high-risk neuroblastoma. JCO. 2006;24(18):9013–9013. https://doi.org/10.1200/jco.2006.24.18_suppl.9013.
Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98(11):2488–94. https://doi.org/10.1002/cncr.11797.
Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr. 2002;214(4):153–6. https://doi.org/10.1055/s-2002-33175.
Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. JCO. 1994;12(12):2607–13. https://doi.org/10.1200/JCO.1994.12.12.2607.
Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials: Moreno Et Al. Pediatr Blood Cancer. 2017;64(1):25–31. https://doi.org/10.1002/pbc.26192.
US Food and Drug Administration. Dinutuximab. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf. [Accessed 20 Jul 2021].
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children’s oncology group. JCO. 2020;38(19):2160–9. https://doi.org/10.1200/JCO.20.00203.
Cheung IY, Cheung N-KV, Modak S, Mauguen A, Feng Y, Basu E, et al. Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression. JCO. 2021;39(3):215–26. https://doi.org/10.1200/JCO.20.01892.
Cheung IY, Hsu K, Cheung N-KV. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. JCO. 2012;30(4):426–32. https://doi.org/10.1200/JCO.2011.37.6236.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. https://doi.org/10.1056/NEJMoa0911123.
Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000. https://doi.org/10.3389/fonc.2020.01000.
Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-Cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https://doi.org/10.3389/fimmu.2019.02664.
Sariola H, Harri T, Rapola J, Saarinen UM. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am J Clin Pathol. 1991;96(2):248–52.https://doi.org/10.1093/ajcp/96.2.248.
Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46(1):440–3.
Balis FM, Busch CM, Desai AV, Hibbitts E, Naranjo A, Bagatell R, et al. The ganglioside G D2 as a circulating tumor biomarker for neuroblastoma. Pediatr Blood Cancer. 2020;67(1):e28031. https://doi.org/10.1002/pbc.28031.
Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung N-K. Humanized 3F8 anti-G D2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial. JAMA Oncol. 2018;4(12):1729. https://doi.org/10.1001/jamaoncol.2018.4005.
Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung N-KV. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology. 2017;6(11):e1358331. https://doi.org/10.1080/2162402X.2017.1358331.
Park JA, Cheung N-KV. Targets and antibody formats for immunotherapy of neuroblastoma. JCO. 2020;38(16):1836–48. https://doi.org/10.1200/JCO.19.01410.
Domogala A, Madrigal JA, Saudemont A. Natural killer cell immunotherapy: from bench to bedside. Front Immunol [Internet]. 2015;6. doi: https://doi.org/10.3389/fimmu.2015.00264.
Arellano. Clinical uses of GM-CSF, a critical appraisal and update. BTT. 2008;13. doi:https://doi.org/10.2147/BTT.S1355.
Kushner BH, Modak S, Basu EM, Roberts SS, Cheung N-KV. High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): efficacy against histologically-evident primary refractory metastases in bone marrow (BM). JCO. 2019;37(15):10024–10024. https://doi.org/10.1200/JCO.2019.37.15_suppl.10024.
Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73(7):1936–41. https://doi.org/10.1182/blood.V73.7.1936.bloodjournal7371936.
Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest. 1986;78(5):1220–8. https://doi.org/10.1172/JCI112705.
Mora J. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Rev Clin Pharmacol. 2016;9(5):647–53. https://doi.org/10.1586/17512433.2016.1160775.
US Food and Drug Administration. Naxitamab. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf [Accessed 8 Jul 2021].
Dhillon S. Dinutuximab: first global approval. Drugs. 2015;75(8):923–7. https://doi.org/10.1007/s40265-015-0399-5.
Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. BTT. 2018;13:1–12. https://doi.org/10.2147/BTT.S114530.
Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs. 2016;8(3):604–16. https://doi.org/10.1080/19420862.2015.1130196.
Ploessl C, Pan A, Maples KT, Lowe DK. Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann Pharmacother. 2016;50(5):416–22. https://doi.org/10.1177/1060028016632013.
Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014;74(5):1047–55. https://doi.org/10.1007/s00280-014-2575-9.
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, et al. A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: children’s oncology group study ANBL0931. Front Immunol. 2018;9:1355. https://doi.org/10.3389/fimmu.2018.01355.
Mora J, Castañeda A, Flores MA, Santa-María V, Garraus M, Gorostegui M, et al. The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy. Results of two consecutive studies. Front Pharmacol. 2020;11:575009. https://doi.org/10.3389/fphar.2020.575009.
Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001;61(10):4244–52.
Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I Focus on gangliosides. Int J Cancer. 1997;73(1):42–9. https://doi.org/10.1002/(sici)1097-0215(19970926)73:1%3c42::aid-ijc8%3e3.0.co;2-1.
Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102(3):688–96. https://doi.org/10.1083/jcb.102.3.688.
Ohmi Y, Kambe M, Ohkawa Y, Hamamura K, Tajima O, Takeuchi R, et al. Differential roles of gangliosides in malignant properties of melanomas. Pizzo SV, editor. PLoS ONE. 2018;13(11):e0206881. doi:https://doi.org/10.1371/journal.pone.0206881.
Casey DL, Lin T-Y, Cheung NKV. Exploiting signaling pathways and immune targets beyond the standard of care for Ewing sarcoma. Front Oncol. 2019;9:537. https://doi.org/10.3389/fonc.2019.00537.
Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma: GD2 as a target in osteosarcoma. Cancer. 2014;120(4):548–54. https://doi.org/10.1002/cncr.28461.
Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47(20):5377–81.
Longee DC, Wikstrand CJ, Mansson J-E, He X, Fuller GN, Bigner SH, et al. Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. Acta Neuropathol. 1991;82(1):45–54. https://doi.org/10.1007/BF00310922.